Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902590 · ClinicalTrials.gov registry record
A Genotype-Phenotype Urothelial Cancer Registry
A clinical trial of Bladder Cancer and Urothelial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 3,519
- Enrollment target
- 4
- Study locations
NCT00902590: Active study of Bladder Cancer and Urothelial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00902590 is a study of Bladder Cancer and Urothelial Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3,519 participants, below the 12,734-participant average among 175 other Bladder Cancer trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00902590, a study of Bladder Cancer and Urothelial Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 3,519 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer. The investigators will look at risk factors to learn more about how these impact cancer. The investigators will also look at genetic markers. These are genes that are found in a known place. They are often associated with a particular trait. If the gene changes in some way, it may predict cancer or response to treatment. The investigators will look for markers in your saliva. This registry will help us develop better methods of: Preventing these cancers. Diagnosing these cancers. Treating these cancers.
Conditions Studied
Interventions
- OTHER saliva sample and questionaire
- OTHER saliva sample, questionaire
Study Locations (4)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,519 participants |
| Start Date | 2009-05 |
| Est. Completion | 2026-05-31 |
What the registry record for NCT00902590 still lists
NCT00902590 is an observational study that tracks outcomes without assigning an intervention. Its 3,519 participants enrollment target places it among the larger protocols in the corpus, below the 12,734-participant average among 175 other Bladder Cancer trials with a reported enrollment target (72% lower).
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which saliva sample and questionaire is the first listed.
NCT00902590 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00902590 about?
NCT00902590 is a clinical study titled "A Genotype-Phenotype Urothelial Cancer Registry". This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer. The investigators will look at risk factors to learn more about how these impact cancer. The investigators...
What is the current status of trial NCT00902590?
This trial is currently active not recruiting. The enrollment target is 3,519 participants. The study started on 2009-05. Estimated completion is 2026-05-31.
What conditions does trial NCT00902590 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Cancer, Ureter Cancer, Renal Pelvis Cancer.
What interventions are being tested in trial NCT00902590?
The interventions under investigation include: saliva sample and questionaire (OTHER), saliva sample, questionaire (OTHER).
Who is sponsoring clinical trial NCT00902590?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00902590 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00902590's enrollment target sits among peer trials
3,519 9th of 175 higher than 167 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia